Article Text

Download PDFPDF
Hospital admissions for bronchiolitis in preterm infants in the absence of respiratory syncytial virus prophylaxis
  1. P Bala,
  2. C A Ryan,
  3. B P Murphy
  1. Department of Paediatrics and Child Health, University College Cork, Ireland;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Respiratory syncytial virus (RSV) is the causative agent in more than 50% of cases of bronchiolitis, with mycoplasma pneumonia, Para influenza 3, adenovirus, and some other viruses accounting for most of the remaining cases. Mortality from bronchiolitis ranges from 1% to 3%. Although as yet there is no safe and effective vaccine, passive immunity with Palivizumab has been shown to reduce hospital admissions of preterm babies, but no reduction in mortality, intensive care admissions, or ventilation days was observed.1 Critical appraisal of this study reveals that the number of infants to …

View Full Text


  • Competing interests: none declared

Linked Articles

  • Fantoms
    Martin Ward Platt